Primary and salvage chemotherapy in advanced Hodgkin's disease: The Milan Cancer Institute experience

G. Bonadonna, A. Santoro, A. M. Gianni, S. Viviani, S. Siena, M. Bregni, R. Zucali, F. Lombardi, V. Bonfante, L. Gianni, P. Valagussa

Research output: Contribution to journalArticlepeer-review

Abstract

This paper reviews the most relevant therapeutic results achieved by the Milan Cancer Institute through successive randomized studies in advanced Hodgkin's disease. The experience achieved confirms the therapeutic importance of an anthracycline-containing regimen such as ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) as salvage treatment and as primary chemotherapy, either when combined with irradiation or cyclically alternated with MOPP (mechlorethamine/vincristine/procarbazine/prednisone). Anthracycline-based combinations can be further refined to decrease toxicity. The biologic aspects of drug-sensitive v drug-resistant tumor cells and the accurate definition of prognostic categories at the time of first treatment failure are also discussed.

Original languageEnglish
Pages (from-to)9-16
Number of pages8
JournalAnnals of Oncology
Volume2
Issue numberSUPPL. 1
Publication statusPublished - 1991

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Primary and salvage chemotherapy in advanced Hodgkin's disease: The Milan Cancer Institute experience'. Together they form a unique fingerprint.

Cite this